Chronic, recurrent Lymphocytic Leukemia Terminated Phase 1 Trials for Ibrutinib (DB09053)

Also known as: Recurrent Chronic Lymphocytic Leukemia

IndicationStatusPhase
DBCOND0112002 (Chronic, recurrent Lymphocytic Leukemia)Terminated1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02614508Buparlisib and Ofatumumab or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic LeukemiaTreatment